The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Vertex Pharmaceuticals (Australia) Pty Ltd
Regulatory activities for this sponsor.
Loading...
Sponsor content
3 result(s) found, displaying 1 to 3
-
Australian Public Assessment Report (AusPAR)Kalydeco (ivacaftor) was approved to treat cystic fibrosis in patients aged 4 months and older who have at least one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Elexacaftor/tezacaftor/ivacaftor and ivacaftor
-